Congenital Adrenal Hyperplasia (CAH)
Summary
Congenital adrenal hyperplasia (CAH) is a group of autosomal recessive disorders affecting adrenal steroidogenesis. The vast majority (~95%) are caused by 21-hydroxylase deficiency (21-OHD), which impairs cortisol and aldosterone synthesis while shunting precursors towards androgen production. The clinical spectrum ranges from the severe "classic" forms (salt-wasting and simple virilising) to the milder "non-classic" form. Classic salt-wasting CAH presents in the first 1-2 weeks of life with life-threatening adrenal crisis (hyponatraemia, hyperkalaemia, shock) and virilisation of female genitalia. Early diagnosis through newborn screening programmes and prompt treatment with glucocorticoid and mineralocorticoid replacement is life-saving. Non-classic CAH presents later with signs of androgen excess (hirsutism, acne, oligomenorrhoea).
Key Facts
- Inheritance: Autosomal recessive; carrier frequency ~1:50 in general population
- Enzyme defect: 21-hydroxylase (CYP21A2) — 95% of CAH
- Pathophysiology: Low cortisol → High ACTH → Adrenal hyperplasia → Excess androgens
- Classic salt-wasting (~75%): Aldosterone + cortisol deficiency; adrenal crisis at 1-2 weeks
- Classic simple virilising (~25%): Cortisol deficiency; excess androgens; no salt-wasting
- Non-classic (late-onset): Mild; androgen excess symptoms; often diagnosed in adolescence/adulthood
- Diagnosis: Elevated 17-hydroxyprogesterone (17-OHP) — blood spot screening
- Treatment: Hydrocortisone + Fludrocortisone (salt-wasters); stress dosing during illness
- Virilisation: Female neonates have ambiguous genitalia (clitoromegaly, labial fusion); males may be undetected until crisis
Clinical Pearls
"A Sick Neonate at 1-2 Weeks = Think CAH": Classic salt-wasting CAH presents around day 7-14 with poor feeding, vomiting, lethargy, and shock. Hyponatraemia + hyperkalaemia should trigger urgent investigation.
"Female with Ambiguous Genitalia = CAH Until Proven Otherwise": Virilised female genitalia (clitoromegaly, fused labia but absent gonads) is the hallmark presentation. The baby is 46,XX but appears masculinised.
"17-OHP Is the Diagnostic Test": Elevated 17-hydroxyprogesterone (17-OHP) confirms 21-hydroxylase deficiency. Newborn screening picks up most cases in screened populations.
"Stress Dosing Saves Lives": Patients with CAH need doubled or tripled hydrocortisone doses during illness/stress. Parents must be educated on emergency management and given IM hydrocortisone for emergencies.
"Boys Present Later or Not at All": Male infants may not show virilisation (they're already male) and can present later with precocious puberty or in life-threatening crisis. Salt-wasting crisis is often the first sign.
Why This Matters Clinically
CAH is a medical emergency in neonates. Undiagnosed salt-wasting CAH is fatal. Early recognition, newborn screening, and lifelong hormone replacement prevent adrenal crises and optimise growth and development. All clinicians should be able to recognise and initiate emergency treatment for adrenal crisis.[1,2]
Incidence & Prevalence
| Parameter | Data |
|---|---|
| Classic CAH incidence | ~1:15,000 live births |
| Non-classic CAH | ~1:1,000 (more common; often undiagnosed) |
| Carrier frequency (21-OHD) | ~1:50 |
| Higher incidence | Ashkenazi Jewish, Alaskan Yupik populations |
Forms of CAH
| Form | Severity | Features | Prevalence |
|---|---|---|---|
| Classic Salt-Wasting | Severe | Cortisol + Aldosterone deficiency; virilisation | ~75% of classic |
| Classic Simple Virilising | Moderate | Cortisol deficiency; virilisation; no salt-wasting | ~25% of classic |
| Non-Classic (Late-Onset) | Mild | Androgen excess only; no cortisol/aldosterone deficiency | 1:1,000 |
Steroidogenesis Pathway
Normal Pathway:
- Cholesterol → Pregnenolone → 17-OH Pregnenolone → 17-OHP → 11-Deoxycortisol → Cortisol
- Aldosterone: Cholesterol → Pregnenolone → Progesterone → DOC → Corticosterone → Aldosterone
21-Hydroxylase Deficiency:
- Blocks conversion of 17-OHP → 11-Deoxycortisol (cortisol pathway)
- Blocks conversion of Progesterone → DOC (aldosterone pathway)
- Result: Precursors (17-OHP, Progesterone) accumulate and shunt to androgen pathway
- ACTH drive increases (low cortisol feedback) → Adrenal hyperplasia
Consequences of Enzyme Block
| Consequence | Mechanism | Clinical Effect |
|---|---|---|
| Low Cortisol | Blocked synthesis | Adrenal insufficiency; hypoglycaemia; poor stress response |
| Low Aldosterone | Blocked synthesis (salt-wasting form) | Hyponatraemia, Hyperkalaemia, Volume depletion, Shock |
| High Androgens | Shunted precursors | Virilisation (female genitalia); precocious puberty |
| Adrenal Hyperplasia | High ACTH drive | Bilateral adrenal enlargement |
Genetic Basis
| Gene | Chromosome | Notes |
|---|---|---|
| CYP21A2 | 6p21 | 21-hydroxylase; most common |
| Pseudogene (CYP21A1P) | Adjacent | Gene conversion/deletion causes disease |
| Mutation severity | Correlates with phenotype | Complete loss = salt-wasting; partial = simple virilising |
Classic Salt-Wasting CAH (Neonates)
Timeline: Presents around day 7-14 of life (after maternal hormones clear)
| Feature | Details |
|---|---|
| Virilised female genitalia | Clitoromegaly; labial fusion; urogenital sinus; 46,XX but appears male; gonads NOT palpable |
| Male neonates | Normal genitalia; may have subtle hyperpigmentation of scrotum |
| Salt-wasting crisis | Poor feeding, vomiting, lethargy, weight loss, dehydration, shock |
| Electrolytes | Hyponatraemia, Hyperkalaemia, Metabolic acidosis |
| Hypoglycaemia | Due to cortisol deficiency |
| Hyperpigmentation | Due to high ACTH (stimulates melanocytes) |
Classic Simple Virilising CAH
| Feature | Details |
|---|---|
| Females | Ambiguous genitalia at birth |
| Males | Normal genitalia; may present later with precocious puberty (early pubic hair, phallic enlargement, advanced bone age) |
| No salt-wasting | Aldosterone production is preserved |
Non-Classic (Late-Onset) CAH
| Feature | Females | Males |
|---|---|---|
| Presentation | Hirsutism, acne, oligomenorrhoea, infertility | Often asymptomatic or mild acne |
| Age at diagnosis | Adolescence/adulthood | Often undiagnosed |
| No virilisation at birth | — | — |
| Mimics | PCOS | — |
Red Flags — Emergency Recognition
[!CAUTION] Adrenal Crisis — Life-Threatening:
- Neonate with poor feeding, vomiting, lethargy at 1-2 weeks
- Hyponatraemia (<130 mmol/L) + Hyperkalaemia (>6 mmol/L)
- Shock, circulatory collapse
- Hypoglycaemia
- Any neonate with ambiguous genitalia
Neonatal Examination
General:
- Lethargy or irritability
- Dehydration (skin turgor, sunken fontanelle, dry mucous membranes)
- Hyperpigmentation (nipples, genitalia)
Genitalia — Female (46,XX):
| Finding | Prader Stage |
|---|---|
| Normal female | Stage 0 |
| Clitoromegaly only | Stage 1 |
| Clitoromegaly + partial labial fusion | Stage 2 |
| Single urogenital opening (urogenital sinus) | Stage 3 |
| Complete labial fusion; phallic structure | Stage 4 |
| Male-appearing; gonads not palpable | Stage 5 |
Key Point: Gonads are NOT palpable in virilised 46,XX females (ovaries are intra-abdominal). In a "male" with undescended testes and hypospadias, consider CAH.
Genitalia — Male:
- Usually normal at birth
- May have scrotal hyperpigmentation
- May present later with precocious puberty
Urgent Investigations (Suspected Adrenal Crisis)
| Test | Expected Finding |
|---|---|
| Electrolytes (U&E) | Hyponatraemia (<130); Hyperkalaemia (>6) |
| Glucose | Hypoglycaemia |
| Blood gas | Metabolic acidosis |
| Cortisol | Low (usually <100 nmol/L) |
| 17-OHP | Markedly elevated (>300 nmol/L in classic) |
| ACTH | Elevated |
| Renin | Elevated (in salt-wasting) |
| Aldosterone | Low (salt-wasting) |
Newborn Screening
| Test | Method | Notes |
|---|---|---|
| 17-OHP blood spot | Heel prick (day 5) | Part of UK Newborn Bloodspot Screening Programme |
| Positive screen | Confirmatory serum 17-OHP + genetic testing |
Confirmatory Tests
| Test | Purpose |
|---|---|
| Serum 17-OHP | Elevated in 21-OHD |
| Synacthen (ACTH stimulation) test | If diagnosis unclear; 17-OHP response |
| Genetic testing (CYP21A2) | Confirms mutation; prenatal genetic counselling |
| Karyotype | Establish genetic sex in ambiguous genitalia |
Additional Investigations
| Investigation | Indication |
|---|---|
| Pelvic ultrasound | Visualise uterus/ovaries in ambiguous genitalia |
| Bone age X-ray | If precocious puberty (advanced bone age) |
| Adrenal imaging | Enlarged adrenals on ultrasound |
Management Algorithm
CAH MANAGEMENT ALGORITHM
↓
┌────────────────────────────────────────────────────────────┐
│ ACUTE ADRENAL CRISIS │
├────────────────────────────────────────────────────────────┤
│ ⚠️ MEDICAL EMERGENCY — DO NOT DELAY │
│ │
│ 1. IV Access + Fluid Resuscitation: │
│ ➤ 0.9% Saline 20 mL/kg bolus; repeat if shocked │
│ ➤ Correct hyponatraemia gradually │
│ │
│ 2. IV Hydrocortisone: │
│ ➤ Neonate: 25 mg IV stat │
│ ➤ Infant: 25-50 mg IV stat │
│ ➤ Child: 50-100 mg IV stat │
│ Then 25-50 mg/m²/day divided q6h │
│ │
│ 3. Correct Hypoglycaemia: │
│ ➤ 10% Dextrose 2 mL/kg bolus if hypoglycaemic │
│ │
│ 4. Correct Hyperkalaemia: │
│ ➤ Insulin-dextrose; calcium gluconate if ECG changes │
│ │
│ 5. Monitor: │
│ ➤ Electrolytes q4-6h until stable │
│ ➤ Blood glucose │
│ ➤ Urine output │
└────────────────────────────────────────────────────────────┘
↓
┌────────────────────────────────────────────────────────────┐
│ MAINTENANCE THERAPY │
├────────────────────────────────────────────────────────────┤
│ GLUCOCORTICOID REPLACEMENT: │
│ ➤ Hydrocortisone 10-15 mg/m²/day in 3 divided doses │
│ ➤ Given TDS (morning, afternoon, evening) │
│ ➤ Lowest effective dose to suppress androgens without │
│ causing Cushing's features or growth suppression │
│ │
│ MINERALOCORTICOID REPLACEMENT (Salt-Wasters): │
│ ➤ Fludrocortisone 50-200 mcg/day (usually 100-150 mcg) │
│ ➤ Salt supplementation in infants (1-2 g NaCl/day) │
│ │
│ MONITORING: │
│ ➤ Growth (height, weight) — quarterly │
│ ➤ Blood pressure — mineralocorticoid excess │
│ ➤ 17-OHP, Androstenedione levels │
│ ➤ Plasma renin (salt-wasters — aim high-normal) │
│ ➤ Bone age annually │
│ ➤ Sodium (especially in infancy) │
└────────────────────────────────────────────────────────────┘
↓
┌────────────────────────────────────────────────────────────┐
│ STRESS DOSING │
├────────────────────────────────────────────────────────────┤
│ ILLNESS RULES: │
│ ➤ Minor illness (fever, viral): Double hydrocortisone │
│ ➤ Moderate illness (gastroenteritis, vomiting): Triple │
│ ➤ Vomiting/unable to take oral: IM Hydrocortisone │
│ │
│ EMERGENCY IM HYDROCORTISONE: │
│ ➤ <1 year: 25 mg IM │
│ ➤ 1-5 years: 50 mg IM │
│ ➤ 6+ years / Adult: 100 mg IM │
│ │
│ SURGERY: │
│ ➤ IV Hydrocortisone: Double dose pre-op + during │
│ ➤ Post-op: Taper slowly to maintenance │
│ │
│ PARENT EDUCATION: │
│ ➤ Steroid emergency card / MedicAlert │
│ ➤ Training for IM hydrocortisone injection │
│ ➤ Never stop steroids suddenly │
└────────────────────────────────────────────────────────────┘
↓
┌────────────────────────────────────────────────────────────┐
│ SURGICAL MANAGEMENT (Feminising Genitoplasty) │
├────────────────────────────────────────────────────────────┤
│ ➤ Controversial and evolving │
│ ➤ May include clitoroplasty, vaginoplasty, labioplasty │
│ ➤ Timing debated: Infancy vs patient-determined │
│ ➤ MDT decision with specialised DSD team │
│ ➤ Psychological support essential │
│ ➤ Informed consent / patient involvement when possible │
└────────────────────────────────────────────────────────────┘
Medication Summary
| Medication | Dose | Purpose |
|---|---|---|
| Hydrocortisone | 10-15 mg/m²/day TDS | Glucocorticoid replacement |
| Fludrocortisone | 50-200 mcg/day (usually 100-150 mcg) | Mineralocorticoid (salt-wasters) |
| Sodium chloride | 1-2 g/day (infants) | Salt supplementation |
Acute Complications
| Complication | Management |
|---|---|
| Adrenal crisis | IV fluids, IV hydrocortisone, electrolyte correction |
| Hypoglycaemia | Dextrose; avoid in future with stress dosing |
| Death | Can occur if undiagnosed/untreated |
Long-Term Complications
| Complication | Notes |
|---|---|
| Short stature | Over-treatment with glucocorticoids OR advanced bone age from androgen excess |
| Obesity | Glucocorticoid excess |
| Testicular adrenal rest tumours (TARTs) | Ectopic adrenal tissue in testes; monitor with ultrasound |
| Ovarian adrenal rest tumours | Rare; may affect fertility |
| Infertility | Due to adrenal rest tumours, irregular menses (women), poor compliance |
| Psychological issues | Especially related to DSD and genital surgery |
With Treatment
| Outcome | Notes |
|---|---|
| Survival | Excellent with newborn screening and treatment |
| Height | Often below mid-parental height; depends on treatment optimisation |
| Fertility | Generally preserved with good control; TARTs affect male fertility |
| Quality of life | Can be excellent; requires lifelong medication and monitoring |
Without Treatment
| Outcome | Notes |
|---|---|
| Salt-wasting CAH | Fatal without treatment (adrenal crisis) |
| Simple virilising CAH | Precocious puberty; short adult stature due to early epiphyseal fusion |
Key Guidelines
| Guideline | Organisation | Year | Key Points |
|---|---|---|---|
| Endocrine Society Clinical Practice Guideline — CAH | Endocrine Society | 2018 | Diagnosis, management, monitoring |
| UK Newborn Screening Programme | PHE / NHS | Ongoing | CAH included in heel prick screen |
Key Evidence
Newborn Screening Impact
- Introduction of newborn screening has virtually eliminated deaths from salt-wasting CAH in screened populations
- Early detection allows treatment before crisis
What is Congenital Adrenal Hyperplasia (CAH)?
CAH is a genetic condition affecting the adrenal glands — small glands above the kidneys that make important hormones. In CAH, the adrenal glands can't make enough of the hormone cortisol, and sometimes aldosterone. This causes the body to make too many male hormones (androgens).
How does it affect babies?
Salt-wasting CAH (most common form):
- Babies can become very unwell in the first 1-2 weeks with vomiting, poor feeding, and dehydration
- This is a medical emergency and needs urgent treatment
Genital differences:
- Baby girls may have genitals that look different (somewhere between male and female) because of too many male hormones
- Baby boys often look normal but can become very sick
How is it treated?
- Hormone replacement: Daily tablets (hydrocortisone to replace cortisol; fludrocortisone to replace aldosterone)
- Salt supplements: Especially for babies
- Sick day rules: Extra doses when unwell
- Emergency injection: Parents are trained to give an injection if the child is vomiting or very unwell
Will my child lead a normal life?
With proper treatment and monitoring, children with CAH grow up to lead healthy, active lives. They need to take medication every day and carry emergency medication.
Guidelines
- Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(11):4043-4088. PMID: 30272171
Key Studies
- Claahsen-van der Grinten HL, Stikkelbroeck NMML, Sweep FCGJ, et al. Fertility in patients with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. 2006;19(5):677-685.
High-Yield Exam Topics
| Topic | Key Points |
|---|---|
| 21-hydroxylase deficiency | 95% of CAH; blocks cortisol + aldosterone synthesis |
| Salt-wasting crisis | Week 1-2; hyponatraemia, hyperkalaemia, shock |
| 17-OHP | Diagnostic marker; elevated in 21-OHD |
| Virilised female | 46,XX with ambiguous genitalia; gonads NOT palpable |
| Treatment | Hydrocortisone + Fludrocortisone; stress dosing |
| Stress dosing | Double dose for illness; IM hydrocortisone for vomiting |
Sample Viva Questions
Q1: A 10-day-old baby presents with poor feeding, vomiting, and lethargy. Sodium is 120 mmol/L and potassium is 7.2 mmol/L. What is your differential and management?
Model Answer: This presentation is highly suspicious for salt-wasting congenital adrenal hyperplasia (21-hydroxylase deficiency). The combination of hyponatraemia, hyperkalaemia, and shock in a neonate at 1-2 weeks is classic. Immediate management: IV access, 0.9% saline bolus 20 mL/kg, IV hydrocortisone 25 mg stat, treat hyperkalaemia (calcium gluconate if ECG changes, insulin-dextrose), check glucose. Investigations: 17-OHP (will be markedly elevated), cortisol, ACTH, renin, aldosterone, blood gas, glucose. Examine genitalia (virilised female?). This is a medical emergency — do not delay treatment waiting for results. Confirmatory: Genetic testing CYP21A2.
Q2: How do you differentiate salt-wasting from simple virilising CAH?
Model Answer: Both forms have cortisol deficiency and androgen excess. The difference is aldosterone:
- Salt-wasting (~75%): Also has aldosterone deficiency; presents with adrenal crisis (hyponatraemia, hyperkalaemia, shock) in first 1-2 weeks; requires fludrocortisone replacement
- Simple virilising (~25%): Aldosterone production is preserved; no salt-wasting crisis; presents with virilisation at birth (females) or precocious puberty (males) Clinically, check plasma renin and aldosterone. Salt-wasters have elevated renin and low aldosterone.
Q3: What are the sick-day rules for a child with CAH?
Model Answer: During illness or stress, cortisol requirements increase. Sick-day rules:
- Minor illness (fever, cold): Double the hydrocortisone dose
- Moderate illness (gastroenteritis, high fever): Triple the hydrocortisone dose
- Vomiting or unable to take oral medication: IM hydrocortisone immediately (25 mg <1 yr; 50 mg 1-5 yrs; 100 mg >6 yrs/adult) and seek medical attention
- Surgery/major procedure: IV hydrocortisone cover perioperatively
Parents must be trained to give IM injections and have emergency hydrocortisone at home. Child should wear a MedicAlert bracelet.
Common Exam Errors
| Error | Correct Approach |
|---|---|
| Not recognising sick neonate as CAH | Hyponatraemia + hyperkalaemia at week 1-2 = CAH |
| Forgetting 17-OHP | 17-OHP is the key diagnostic marker |
| Not knowing stress dosing | Double/triple dose during illness; IM if vomiting |
| Thinking virilised "male" has testes | In 46,XX virilisation, gonads are NOT palpable (ovaries intra-abdominal) |
Last Reviewed: 2025-12-24 | MedVellum Editorial Team
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.